Anzeige
❌
Mehr »
Montag, 05.10.2026 - Börsentäglich über 12.000 News
Die Jobs, die keine KI der Welt ersetzen kann - und das Unternehmen dahinter
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2QQQ4 | ISIN: SE0015658570 | Ticker-Symbol: N/A
Frankfurt
10.04.26 | 08:18
0,000 Euro
0,00 % 0,000
1-Jahres-Chart  (nicht börsennotiert)
NOVAKAND PHARMA AB Chart 1 Jahr

Aktuelle News zur NOVAKAND PHARMA

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
10.04.XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 10.04.20261.771The following instruments on Boerse Frankfurt do have their last trading day on 10.04.2026.Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 10.04.2026.ISIN NameAU000000ICI5...
► Artikel lesen
NOVAKAND PHARMA Aktie jetzt für 0€ handeln
26.03.Novakand Pharma AB - Removal from trading on Nasdaq First North Growth Market514According to section 2.3.7 of the Nasdaq First North Growth Market Rulebook, an issuer shall be able to demonstrate ongoing business operations. According to section 8.2.7 of the Nasdaq First...
► Artikel lesen
02.03.Novakand Pharma AB: Novakand's Board of Directors proposes new business direction and relisting to be presented at Extraordinary General Meeting426BackgroundNovakand Pharma AB ("Novakand" or the "Company") announced on February 24, 2026, that Nasdaq had rejected Novakand's application for continued listing on First North Growth Market following...
► Artikel lesen
25.02.Novakand Pharma AB: The board evaluates Novakand Pharma's options after the decision not to execute the planned reverse take over of SVF Vaccines433On February 24, 2026, Novakand Pharma AB (publ) ("Novakand" or "the Company") announced that Nasdaq has rejected Novakand's application for approval of continued listing on the First North Growth Market...
► Artikel lesen
24.02.KDventures AB: KDventures's portfolio company SVF Vaccines announces that the intended merger with Novakand Pharma will not be carried out following negative decision from Nasdaq522STOCKHOLM, Sweden, February 24, 2026. KDventures AB (Nasdaq Stockholm: KDV) announces that the planned reversed acquisition of the portfolio company SVF Vaccines by Novakand Pharma will not be completed...
► Artikel lesen
24.02.The observation status for Novakand Pharma AB is updated382On November 25, 2025, the shares in Novakand Pharma AB (the "Company") were given observation status with reference to the Company's disclosure of its interim report for the third quarter of 2025....
► Artikel lesen
12.02.Novakand Pharma AB: Novakand Pharma applies for Nasdaq's approval of continued listing of the combined company post a completed reverse takeover with SVF Vaccines354Novakand Pharma AB (publ) ("Novakand" or "the Company") has previously reported that the Company has entered into a share purchase agreement with the shareholders of SVF Vaccines AB ("SVF") for a reverse...
► Artikel lesen
06.02.Karolinska Development AB (publ): Karolinska Development's portfolio company SVF Vaccines and Novakand Pharma enters into a reverse acquisition agreement381STOCKHOLM, Sweden, February 6, 2026. Karolinska Development AB (Nasdaq Stockholm: KDEV) announces that its portfolio company SVF Vaccines has entered into a reverse acquisition agreement with Novakand...
► Artikel lesen
22.12.25The observation status for Novakand Pharma AB is updated550On November 25, 2025, the shares in Novakand Pharma AB (the "Company") were given observation status with reference the Company's disclosure of its interim report for the third quarter of 2025. The...
► Artikel lesen
25.11.25Novakand Pharma AB receives observation status525On November 21, 2025, Novakand Pharma AB (the "Company") disclosed its interim report for the third quarter of 2025. The press release also included information on, inter alia, the board of directors'...
► Artikel lesen
21.11.25Novakand Pharma AB: Interim Report Third Quarter 2025, July 1 - September 30 Novakand Pharma AB (publ.), org.no. 556806-8851340The period in brief - financial summary for the third quarter 2025Net sales amounted to SEK 0 million (SEK 0 million).R&D expenses amounted to SEK 4,0 million (SEK 10,2 million).Operating loss before...
► Artikel lesen
11 Nachrichten in den letzten 12 Monaten